Advances in drug resistance of osteosarcoma caused by pregnane X receptor.

IF 3.4 2区医学 Q2 PHARMACOLOGY & PHARMACY

Drug Metabolism Reviews Pub Date : 2024-06-13 DOI:10.1080/03602532.2024.2366948

Kunhong Mao, Can Liu, Zhongwen Tang, Zhouzhou Rao, Jie Wen

{"title":"Advances in drug resistance of osteosarcoma caused by pregnane X receptor.","authors":"Kunhong Mao, Can Liu, Zhongwen Tang, Zhouzhou Rao, Jie Wen","doi":"10.1080/03602532.2024.2366948","DOIUrl":null,"url":null,"abstract":"<p><p>Osteosarcoma (OS) is a prevalent malignancy among adolescents, commonly manifesting during childhood and adolescence. It exhibits a high degree of malignancy, propensity for metastasis, rapid progression, and poses challenges in clinical management. Chemotherapy represents an efficacious therapeutic modality for OS treatment. However, chemotherapy resistance of OS is a major problem in clinical treatment. In order to treat OS effectively, it is particularly important to explore the mechanism of chemotherapy resistance in OS.The Pregnane X receptor (PXR) is a nuclear receptor primarily involved in the metabolism, transport, and elimination of xenobiotics, including chemotherapeutic agents. PXR involves three stages of drug metabolism: stage I: drug metabolism enzymes; stage II: drug binding enzyme; stage III: drug transporter.PXR has been confirmed to be involved in the process of chemotherapy resistance in malignant tumors. The expression of PXR is increased in OS, which may be related to drug resistance of OS. Therefore, wereviewed in detail the role of PXR in chemotherapy drug resistance in OS.</p>","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Metabolism Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03602532.2024.2366948","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Osteosarcoma (OS) is a prevalent malignancy among adolescents, commonly manifesting during childhood and adolescence. It exhibits a high degree of malignancy, propensity for metastasis, rapid progression, and poses challenges in clinical management. Chemotherapy represents an efficacious therapeutic modality for OS treatment. However, chemotherapy resistance of OS is a major problem in clinical treatment. In order to treat OS effectively, it is particularly important to explore the mechanism of chemotherapy resistance in OS.The Pregnane X receptor (PXR) is a nuclear receptor primarily involved in the metabolism, transport, and elimination of xenobiotics, including chemotherapeutic agents. PXR involves three stages of drug metabolism: stage I: drug metabolism enzymes; stage II: drug binding enzyme; stage III: drug transporter.PXR has been confirmed to be involved in the process of chemotherapy resistance in malignant tumors. The expression of PXR is increased in OS, which may be related to drug resistance of OS. Therefore, wereviewed in detail the role of PXR in chemotherapy drug resistance in OS.

查看原文本刊更多论文

孕烷 X 受体导致骨肉瘤耐药性的研究进展。

骨肉瘤（Osteosarcoma，OS）是青少年中一种常见的恶性肿瘤，通常在儿童和青少年时期发病。骨肉瘤恶性程度高、易转移、进展快，给临床治疗带来了挑战。化疗是治疗 OS 的有效治疗方式。然而，OS 的化疗耐药性是临床治疗中的一大难题。孕烷X受体（PXR）是一种核受体，主要参与包括化疗药物在内的异种生物的代谢、转运和清除。PXR 涉及药物代谢的三个阶段：第一阶段：药物代谢酶；第二阶段：药物结合酶；第三阶段：药物转运体。PXR已被证实参与了恶性肿瘤的化疗耐药过程，而PXR在OS中的表达增加，可能与OS的耐药性有关。因此，我们详细研究了PXR在OS化疗耐药中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Metabolism Reviews 医学-药学

CiteScore

11.10

自引率

1.70%

发文量

审稿时长

1 months

期刊介绍： Drug Metabolism Reviews consistently provides critically needed reviews of an impressive array of drug metabolism research-covering established, new, and potential drugs; environmentally toxic chemicals; absorption; metabolism and excretion; and enzymology of all living species. Additionally, the journal offers new hypotheses of interest to diverse groups of medical professionals including pharmacologists, toxicologists, chemists, microbiologists, pharmacokineticists, immunologists, mass spectroscopists, as well as enzymologists working in xenobiotic biotransformation.